Stephens reaffirmed their equal weight rating on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report released on Wednesday, Benzinga reports. They currently have a $4.00 price target on the stock. Several other research analysts have also commented on OCX. Benchmark reaffirmed a speculative buy rating and set a $5.00 price objective on […]